Executive Briefing Series (formerly The Food & Drug Letter)
Oct. 5, 2012
Risk Minimization Leads Causes of Drug Ad Enforcement Letters
Drugmakers’ omissions or minimizations of product risks are the leading cause of FDA enforcement letters for advertising, accounting for 70 of the 120 letters sent to pharma companies since 2009, experts say.
This article is viewable by subscribers only. To view this article, please select an option below.